ClinicalTrials.gg
TerminatedNCT00376181Updated Jun 22, 2010

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Pioglitazone and Azilsartan and Pioglitazone and Azilsartan in Type 2 Diabetes, sponsored by Takeda. Terminated at 73 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-06-22.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Why this study was terminated
Combination formulation concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
66th of 122
96 · median 103
Started
2006
with 8 others
Phase 3
31 of 122
1 open now
Registered
19th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 66th largest by enrollment, is one of 9 that started in 2006, is one of 31 in phase 3, and was the 19th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.

Read the detailed description

Type 2 diabetes is a chronic disease. In the United States, an estimated 21 million people have diabetes, with type 2 diabetes occurring in 90% to 95% of cases. Hypertension (high blood pressure) affects approximately 50 million individuals in the United States. The association of diabetes and hypertension is increased in this population; hypertension is more common in persons with diabetes while individuals with hypertension are 2.5 times more likely to develop diabetes than those who have normal blood pressure. As a result, more than 70% of adults with diabetes have hypertension (defined as having blood pressure greater than or equal to 130/80 mm Hg or using prescription medication for hypertension).

Patients with type 2 diabetes and hypertension are at high risk of other illnesses and death. Diabetes and hypertension are associated with insulin resistance (normal amounts of insulin are no adequate to produce a normal insulin response from fat, muscle and liver cells). and hyperinsulinemia (excess levels of insulin in the blood), which are independent risk factors for cardiovascular (heart vessel) disease. Individuals with type 2 diabetes carry a 2 to 4- time greater risk of cardiovascular disease and stroke compared with the general population. Uncontrolled hypertension also is associated with an increased risk of cardiovascular disease and stroke.

Takeda Global Research and Development Center, Inc. is developing a fixed-dose combination product, AD-4833-536. AD-4833-536 is a combination of AD-4833 (pioglitazone) and TAK-536 (azilsartan). Pioglitazone is an oral antidiabetic agent that acts by reducing insulin resistance and approved for treatment of adult patients with type 2 diabetes mellitus. Azilsartan is a angiotensin II receptor blocker that modulates the renin-angiotensin-aldosterone system that regulates blood pressure.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • type 2 diabetes
  • hypertension
  • blood pressure
  • diastolic blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes with glycosylated of greater than or equal to 9.0 to less than or equal to 11.0% at Screening.
  • Documented hypertension.
  • On a stable diet and exercise program in addition to metformin alone or combination of metformin and a sulfonylurea for a minimum of 8 weeks prior to screening.
  • If receiving antihypertensive therapy, must be on no more than 3 agents and be on a stable regimen.
  • Clinical laboratory evaluations (including clinical chemistry, hematology, and urinalysis) within the reference range unless the results are deemed not for inclusion into this study by the investigator.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria

  • Type 1 diabetes mellitus.
  • Diastolic blood pressure greater than 104 mm Hg at randomization visit.
  • Currently taking an angiotensin II-receptor blocker.
  • Unstable angina or heart failure of any etiology with functional class III or IV.
  • History of myocardial infarction, cerebrovascular accident (stroke), percutaneous coronary intervention, coronary artery bypass graft or within the previous six months.
  • cardiac conduction defects.
  • Secondary hypertension of any etiology.
  • greater than 45 kg/m2
  • Has significant renal dysfunction.
  • History of drug abuse or a history of alcohol abuse within the past 2 years.
  • Previous history of cancer, other than basal cell carcinoma or stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
  • or aspartate transaminase level of greater than 2.5 times the , active liver disease, or jaundice.
  • Serum potassium greater than the upper limit of normal.
  • Currently participating in another study or has participated in an investigational study within 30 days prior to Randomization.
  • Any other serious disease or condition that would compromise subject safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
  • Is hypersensitive to angiotensin II receptor blockers.
  • Is hypersensitive to thiazolidinediones.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • any anti-diabetic agent (including thiazolidinediones and/or insulin) except for metformin or a combination of metformin and a sulfonylurea
    • niacin more than 200mg per day
    • tricyclic antidepressants or phenothiazines
    • Angiotensin II receptor blockers
    • Thiazolidinediones
    • Insulin
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Pioglitazone 45 mg/Azilsartan 20 mg QD

    Drug: Pioglitazone and Azilsartan

  • Experimental
    Pioglitazone 45 mg/Azilsartan 40 mg QD

    Drug: Pioglitazone and Azilsartan

  • Active comparator
    Pioglitazone 45 mg QD

    Drug: Pioglitazone

Interventions

  • DrugPioglitazone and Azilsartan

    Drug pages: Pioglitazone · Azilsartan

    Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.

    Also known as: Actos, AD-4833, TAK-536

  • DrugPioglitazone and Azilsartan

    Drug pages: Pioglitazone · Azilsartan

    Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.

    Also known as: Actos, AD-4833, TAK-536

  • Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.

    Also known as: Actos, AD-4833

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Glycosylated Hemoglobin.

    The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or including final visit, and Glycosylated Hemoglobin collected at baseline.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change from Baseline in Diastolic Blood Pressure

    The change between Diastolic Blood Pressure measured at each week indicated including final visit and Diastolic Blood Pressure measured at baseline.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24.

  2. Change from Baseline in Systolic Blood Pressure

    The change between Systolic Blood Pressure measured at each week indicated including final visit and Systolic Blood Pressure measured at baseline.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24

07

Study locations

73 sites
  • Huntsville, Alabama, United States
  • Tallassee, Alabama, United States
  • Little Rock, Arkansas, United States
  • Auburn, California, United States
  • Bakersfield, California, United States
  • Buena Park, California, United States
  • Chula Vista, California, United States
  • Huntington Park, California, United States
  • Los Gatos, California, United States
  • Norwalk, California, United States
  • Orangevale, California, United States
  • Sacramento, California, United States
  • Stockton, California, United States
  • Deerfield Beach, Florida, United States
  • Hialeah, Florida, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Kissimmee, Florida, United States
  • Marianna, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Pembroke Pines, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Dunwoody, Georgia, United States
  • Chicago, Illinois, United States
  • Bloomington, Indiana, United States
  • Evansville, Indiana, United States
  • Shawnee Mission, Kansas, United States
  • Prince Frederick, Maryland, United States
  • Livonia, Michigan, United States
  • St. Clair Shores, Michigan, United States
  • Las Vegas, Nevada, United States
  • Trenton, New Jersey, United States
  • Albany, New York, United States
  • Johnson City, New York, United States
  • Staten Island, New York, United States
  • Charlotte, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Marion, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Buckingham, Pennsylvania, United States
  • Jeannette, Pennsylvania, United States
  • Mt. Pleasant, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Bristol, Tennessee, United States
  • New Tazewell, Tennessee, United States
  • Dallas, Texas, United States
  • El Paso, Texas, United States
  • Euless, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • McKinney, Texas, United States
  • Midland, Texas, United States
  • North Richland Hills, Texas, United States
  • San Antonio, Texas, United States
  • Falls Church, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Santa Fe, Argentina
  • Santiago, Chile
  • Temuco, Chile
  • Leon, Guanajuato, Mexico
  • Zapopan, Jalisco, Mexico
  • Monterrey, NL, Mexico
  • Guadalajara, Mexico
  • Mexico, DF, Mexico
  • Arequipa, Peru
  • Lambayeque, Peru
  • Lima, Peru
  • Trujillo, Peru
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2006
First posted
Sep 14, 2006
Start
Jun 2006
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Jun 22, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00376181
Lead sponsor
Takeda
First posted
Sep 14, 2006
Start date
Jun 2006
Primary completion
May 2007
Completion
May 2007
Last update
Jun 22, 2010

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Azilsartan

Start the discussion